Warm Autoimmune Hemolytic Anemia Market is Expected to Witness Growth at an Accelerated CAGR of 14.7% in the 7MM for the Study Period 2018-30, Assesses DelveInsight

LAS VEGAS, Feb. 28, 2022 /PRNewswire/ -- The launch of key Warm Autoimmune Hemolytic Anemia (WAIHA) assets such as Fostamitinib (Rigel Pharmaceuticals) and APL2 (Apellis Pharmaceuticals), which have already taken a head start in the race of capping a higher market share. The WAIHA market growth during the forecast period as the approval of these therapies will be a milestone for WAHIA patients. Fostamatinib is a first of its kind oral spleen tyrosine kinase (SYK) inhibitor, which is commercially available in the US under the brand name TAVALISSE. The drug has already obtained the FDA orphan drug designation in 2018 along with positive Phase II results. In January 2021, the FDA also granted Fast Track designation to Fostamatinib for the WAIHA treatment.

DelveInsight's Warm Autoimmune Hemolytic Anemia Market report offers a detailed comprehension of the Warm Autoimmune Hemolytic Anemia Market size by treatment, epidemiology, emerging therapies, Autoimmune Hemolytic Anemia Market share of the individual therapies, historic current and forecasted Warm Autoimmune Hemolytic Anemia Market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

Some of the key highlights from the Warm Autoimmune Hemolytic Anemia Market Insight report

• The Warm Autoimmune Hemolytic Anemia (WAIHA) market size in the United States was estimated at around USD 297 million in 2020, and the market is expected to surge during the study period (2018–2030).
• According to DelveInsight estimates, the total Warm Autoimmune Hemolytic Anemia prevalent population in the 7 MM was found to be 89,747 cases in 2020.
• Key Warm Autoimmune Hemolytic Anemia pharma players working proactively in the market are Rigel Pharmaceuticals, Apellis Pharmaceuticals, Johnson & Johnson, Immunovant, Alexion Pharmaceuticals, Sanofi, Incyte Corporation, Annexon, Janssen Pharmaceuticals, Momenta Pharmaceuticals, Alexion and others have the potential to create a significant positive shift in the Warm Autoimmune Hemolytic Anemia market size. 
• The launch of emerging therapies in the Warm Autoimmune Hemolytic Anemia market space such as APL-2, Fostamatinib/R935788, M281, IMVT-1401, ALXN1830, and others will significantly impact the Warm Autoimmune Hemolytic Anemia market during the forecast period.
• According to DelveInsight's analysis, females are affected more as compared to males in the case of Warm Autoimmune Hemolytic Anemia.

Explore more about the therapies set to grab substantial Warm Autoimmune Hemolytic Anemia market share @ Warm Autoimmune Hemolytic Anemia Treatment Landscape 

Warm Autoimmune Hemolytic Anemia Overview

Autoimmune Hemolytic Anemia (AIHA) is an acquired hemolytic disorder where antibodies directed against red blood cell (RBC) surface epitopes cause premature RBC destruction, which leads to anemia. Although rare, Autoimmune Hemolytic Anemia is one of the most common forms of acquired hemolytic disorders. Based on the isotype and thermal characteristics of the autoantibody, Autoimmune Hemolytic Anemia has been traditionally divided into warm forms, cold agglutinin disease (CAD), and rarer forms—mixed, atypical, and paroxysmal cold hemoglobinuria. Warm Autoimmune Hemolytic Anemia (WAIHA) is the most common type of Autoimmune Hemolytic Anemia, comprising approximately 70–80% of all adult cases and 50% of pediatric cases. More than half of these cases are called primary due to undefined etiology.

Request for a Webex demo of the report @ Warm Autoimmune Hemolytic Anemia Sample Report

Warm Autoimmune Hemolytic Anemia Epidemiology Segmentation

As per DelveInsight, the total 7MM prevalent cases of Warm Autoimmune Hemolytic Anemia are anticipated to increase during the study period; the total prevalent population will reach 93,055 cases by 2030. The segmentation is based on:

1. Total Prevalent Cases of WAIHA
2. Diagnosed Prevalence of WAIHA
3. Type-specific Prevalence of WAIHA
4. Gender-specific Prevalence of WAIHA

DelveInsight's analysts indicates that the total diagnosed Warm Autoimmune Hemolytic Anemia cases in the 7MM were 1,577,979 in 2020. These cases are expected to rise by 2030, during the forecast period.

Also, as per DelveInsight's estimates, the total number of Warm Autoimmune Hemolytic Anemia prevalence in the 7 MM was found to be 89,747 cases in 2020.

The Warm Autoimmune Hemolytic Anemia Market Report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into

• Total Prevalent Warm Autoimmune Hemolytic Anemia Cases 
• Diagnosed Warm Autoimmune Hemolytic Anemia Prevalence
• Type-specific Warm Autoimmune Hemolytic Anemia Prevalence 
• Gender-specific Warm Autoimmune Hemolytic Anemia Prevalence

Know-how Warm Autoimmune Hemolytic Anemia (WAIHA) Market Epidemiological Trends are going to look like in 2030 for the 7 MM by downloading @ Warm Autoimmune Hemolytic Anemia Market  Epidemiological Insights

Warm Autoimmune Hemolytic Anemia Market 

The traditional Warm Autoimmune Hemolytic Anemia treatment options include corticosteroids, splenectomy, and conventional immunosuppressive drugs. Over the years, however, newer options have become available with considerable evidence of success. The Warm Autoimmune Hemolytic Anemia pipeline scenario is showing early promise with several therapeutic candidates at different stages of clinical development. Many new Warm Autoimmune Hemolytic Anemia therapies are under development, many of which have novel targets and mechanisms of action. 

Among the Warm Autoimmune Hemolytic Anemia emerging drugs, Fostamatinib/R935788 is in the late development stages. Rigel Pharmaceuticals is developing R935788 for the treatment of Warm Autoimmune Hemolytic Anemia based on significant medical needs. R935788 is a tyrosine kinase inhibitor with demonstrated activity against spleen tyrosine kinase (SYK). It is currently in the Phase III clinical trial for Warm Antibody Autoimmune Hemolytic Anemia treatment. Apart from that, APL-2 (Apellis Pharmaceuticals) is currently in the Phase II stage of clinical development and M281 is being investigated by Janssen Pharmaceuticals as potential Warm Autoimmune Hemolytic Anemia treatment therapies to be made available in the market in the future.

Learn more about the current and emerging treatments @ Warm Autoimmune Hemolytic Anemia Therapeutics Assessment

Warm Autoimmune Hemolytic Anemia Pipeline Therapies and Key Players

• APL-2: Apellis Pharmaceuticals
• Fostamatinib/R935788: Rigel Pharmaceuticals
• M281: Janssen Pharmaceuticals
• IMVT-1401: Immunovant
• ALXN1830: Alexion 

To know about more pipeline therapies under different development phases visit @ Warm Autoimmune Hemolytic Anemia Market Pipeline Assessment

Warm Autoimmune Hemolytic Anemia Market Dynamics

Market Drivers for WAIHA:

• The increasing patient population is the key reason for the worldwide Warm Autoimmune Hemolytic Anemia market growth. 
• Another important element influencing the market expansion for WAIHA is Advancement in research and development. 
• Improved clinical trials 
• Development of new therapeutic agents that might give a cure for the condition and enhance the treatment management.
• Increase in WAIHA marketed drugs.

Market Barriers for WAIHA:

• Increasing refractory cases provide significant challenges for physicians, which is causing complications in treatment processes.
• Additional comorbidities along with the disease itself are creating hurdles in the treatment procedures, and deteriorating the efficiency of medications.
• The lack of disease understanding degrades the overall patient management.
• Despite the availability of several immunosuppressive therapies, there is a dearth of curative medicines that might bring a lasting cure to patients

The increase in Warm Autoimmune Hemolytic Anemia prevalence is considered to be the major driving force for Warm Autoimmune Hemolytic Anemia market size growth in the coming years.

Know which therapy is expected to score the touchdown first @ Warm Autoimmune Hemolytic Anemia Market Forecast

Scope of the Warm Autoimmune Hemolytic Anemia Market Report

• Study Period: 2018-30
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Warm Autoimmune Hemolytic Anemia Companies: Rigel Pharmaceuticals, Apellis Pharmaceuticals, Johnson & Johnson, Immunovant, Alexion Pharmaceuticals, Sanofi, Incyte Corporation, Annexon, Janssen Pharmaceuticals, Momenta Pharmaceuticals, Alexion
• Key Warm Autoimmune Hemolytic Anemia Pipeline Therapies: APL-2, Fostamatinib/R935788, M281, IMVT-1401, ALXN1830
• Warm Autoimmune Hemolytic Anemia Therapeutic Assessment: Warm Autoimmune Hemolytic Anemia Market  current marketed and emerging therapies
• Warm Autoimmune Hemolytic Anemia Market  Dynamics: Warm Autoimmune Hemolytic Anemia Market drivers and barriers 
• Competitive Intelligence Analysis: Porter's five forces, SWOT analysis, PESTLE analysis, Market  entry strategies, BCG Matrix, Unmet Needs
• KOL views
• Reimbursement Scenario

Discover more about the future market share of Warm Autoimmune Hemolytic Anemia treatment therapies @ Warm Autoimmune Hemolytic Anemia Future Outlook

Table of Contents 

Get in touch with our Business executive @ Warm Autoimmune Hemolytic Anemia Treatment Layout

Related Reports

Warm Autoimmune Hemolytic Anemia Pipeline

DelveInsight's "Warm Autoimmune Hemolytic Anemia Pipeline Insights, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Warm Autoimmune Hemolytic Anemia pipeline landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further covers key Warm Autoimmune Hemolytic Anemia companies involved such as Immunovant Sciences GmbH, Apellis Pharmaceuticals, Bioverativ, and others.

Warm Autoimmune Hemolytic Anemia Epidemiology 

DelveInsight's 'Warm Autoimmune Hemolytic Anemia Epidemiology Forecast to 2030' report delivers an in-depth understanding of Warm autoimmune hemolytic anemia, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Iron Deficiency Anemia Market 

DelveInsight's 'Iron Deficiency Anemia Market Insights, Epidemiology and Market Forecast - 2030' report delivers an in-depth understanding of the IDA, historical and forecasted epidemiology, as well as the IDA market trends, market drivers, market barriers, and key Iron Deficiency Anemia companies, involved such as Akebia Therapeutics, Shield Therapeutics, AMAG Pharmaceuticals, Pharmacosmos Therapeutics, Vifor Pharma, American Regent, MegaPro Biomedical, Nemysis, and others.

Iron Deficiency Anemia Epidemiology 

DelveInsight's 'Iron Deficiency Anemia Epidemiology Forecast to 2030' report delivers an in-depth understanding of the IDA across the several selected cancer types, historical and forecasted IDA epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Anemia in Chronic Kidney Disease Pipeline

DelveInsight's "Anemia in Chronic Kidney Disease Pipeline Insights, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Anemia in Chronic Kidney Disease pipeline landscape. The report also covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers key Anemia in Chronic Kidney Disease companies involved such as Pieris Pharmaceuticals, Jiangsu HengRui Medicine, Shenyang Sunshine Pharmaceutical, Biocad, Xenetic Biosciences, Chiasma, Liminal BioSciences, Acceleron Pharma, Celgene Corporation, and several others.

Aplastic Anemia Pipeline

DelveInsight's "Aplastic Anemia Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in the Aplastic Anemia pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers key Aplastic Anemia companies involved such as Pfizer, Regeneron Pharmaceuticals, Regen BioPharma, Omidubicel, Cellenkos, Hemogenyx, and many others.

Browse Through Our Blog Posts

• Warm Autoimmune Hemolytic Anemia: A less prevalent disease with prevailing unmet needs
• Iron Deficiency Anemia Market Growth Anticipated to Fuel at a CAGR of 3.7% by 2030
• Warm Autoimmune Hemolytic Anemia Epidemiology forecast segmentation, treatment approaches, and WAIHA market forecast
• Overcoming the prevailing unmet needs in Beta-Thalassemia Market

Assessing leakage for application of strategic counter by Competitive Intelligence 

About DelveInsight

DelveInsight is a pioneer in stipulating state-of-the-art services to the clients, also serving as a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect With Us at LinkedIn | Facebook | Twitter

Contact Us
Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg